Personal record-keeping and educational reference. 18+. The app does not recommend substances, doses or treatment, or determine whether a substance is safe, approved or appropriate for you. Consult a qualified healthcare professional about decisions involving your health.
‹ Library

Ipamorelin

Growth Hormone SecretagogueResearch Use Only

Also known as: NNC 26-0161

The gentlest growth-hormone-releasing peptide — GH release with little effect on hunger or stress hormones.

Dosing quick reference

research reference
Starting dose
100 mcg once daily (bedtime)
Frequency
Once daily (bedtime, empty stomach)
Typical range
100–300 mcg per day
Cycle
8–12 weeks on, then 2–4 weeks off
Titration (step-up)
Wk 1–2: 100 → Wk 3–4: 150 → Wk 5–8: 200 → Wk 9+: 250 mcg
Half-life
~2 hours
Route
Subcutaneous (research)
Common use
Studied as a selective growth-hormone secretagogue in growth-hormone axis research
Common vial sizes
5 mg · 10 mg
Storage
Lyophilized powder stored refrigerated or frozen away from light; reconstituted solution refrigerated (2–8 °C) and used within a few weeks
Stacking notes
Commonly paired with a GHRH analog such as CJC-1295 (with or without DAC) in research discussions

Reported side effects

Injection-site reactionTransient headache reported anecdotallyHead-rush or flushing reported anecdotally
Regulatory note: Not an approved therapeutic; sold for research purposes only
Calculate a dose →Ipamorelin on The Peptide Guide →Deeper research reference: literature dose ranges, storage and handling, and where to source in Canada.

Dose figures are ranges commonly referenced in research literature, not recommendations or medical advice. Research-only labeling does not establish that a substance is safe, approved or appropriate for personal use. Consult a qualified healthcare professional about health decisions.